| Cash Flow | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Amortization of debt issuance costs and discounts | 0 | 0 | 53,722 |
| Accrued expenses | - | - | -453,445 |
| Accrued interest - related party | - | 0 | - |
| Change in fair value of derivative liabilities | 0 | 0 | 6,312 |
| Accrued interest | 0 | 0 | 14,190 |
| Gain on extinguishment of debt | 0 | 0 | 326,345 |
| Net loss | -1,205,312 | -1,146,096 | -5,167,569 |
| Stock-based compensation | 193,806 | 345,396 | 496,864 |
| Shares issued in exchange for services | 250,000 | - | 250,000 |
| Prepaid expenses and other current assets | - | - | 148,531 |
| Prepaid expenses | -93,844 | -88,282 | - |
| Accounts payable - trade | 260,275 | -140,781 | 496,910 |
| Accrued expenses | -42,777 | 256,901 | - |
| Net cash used in operating activities | -450,164 | -596,298 | -4,777,892 |
| Repayment of notes payable- related party | 0 | 0 | 275,000 |
| Proceeds from issuance of common stock and warrants in private placement | 0 | 0 | 7,161,504 |
| Repayment of financing liability | 78,490 | 92,407 | - |
| Proceeds from issuance of common stock pursuant to warrant exercises | 669,106 | - | - |
| Proceeds from issuance of common stock in private placement | 260,000 | 652,000 | - |
| Payment of issuance costs related to private placement | 31,273 | 121,160 | 1,683,523 |
| Net cash provided by financing activities | 819,343 | 438,433 | 5,202,981 |
| Net increase in cash and cash equivalents | 369,179 | -157,865 | 425,089 |
| Cash and cash equivalents - beginning of period | 301,309 | 459,174 | 34,085 |
| Cash and cash equivalents - end of period | 670,488 | 301,309 | 459,174 |
ADAPTIN BIO, INC. (APTN)
ADAPTIN BIO, INC. (APTN)